Immunohistochemical staining of Microphthalmia Transcription Factor  of human FFPE tissue followed by incubation with HRP labeled secondary and development with DAB substrate.

Microphthalmia Transcription Factor [D5] Antibody (cGMP).

$ 135.00$ 605.00
Please Select Product Options Below To View The Catalog Number.

SKU: QIVD306
Species: Human
Tested Applications: IHC [IVD]
Available Conjugates:
Isotype: Mouse IgG1

Product NumberDescriptionPrice
QIVD306-0.1ml Size: 0.1 ml, Format: Concentrate $ 135.00
QIVD306-0.5ml Size: 0.5 ml, Format: Concentrate $ 395.00
QIVD306-1ml Size: 1 ml, Format: Concentrate $ 605.00
QIVD306-6ml Size: 6 ml, Format: Predilute $ 165.00
Shipping Information
In Stock
Flat Rate Shipping Anywhere in the US: $45
Datasheets and Documentation
Product Datasheet
Certificate of Analysis and Tags (Coming Soon)
Lot Number:

Expiration Date:

Concentration (Write Lyophilized if Lyophilized):

Reconsitution Instructions (Leave Blank if Liquid):

Manufacture Date:

Purity:

Bioactivity (test results eg. IU/ml):


SKU: QIVD306-0.1ml
Microphthalmia Transcription Factor General Information
Alternate Names
Molecular Weight
58.8 kDa
Chromosomal Location
p13 [chr: 3] [chr_start: 69739435] [chr_end: 69968337] [strand: 1]
Curated Database and Bioinformatic Data
Gene SymbolMITF
Entrez Gene ID4286
RefSeq Protein Accession(s)XP_005264812; NP_937802; XP_005264811; NP_001171896; NP_937820; XP_016861933; XP_016861937; NP_006713; NP_000239; NP_937801; NP_937821
RefSeq mRNA Accession(s)NM_001354606; NM_198158; NM_001354607; NM_006722; NM_198159; NM_001184967; NM_000248; NM_001354605; NM_198177; NM_001184968; NM_001354608; NM_001354604; NM_198178
RefSeq Genomic Accession(s)NC_000003; NG_011631
UniProt ID(s)O75030
PharmGKB ID(s)PA30823
KEGG Gene ID(s)hsa:4286
Associated Diseases (KEGG IDs)Waardenburg syndrome 2A (WS2A) [MIM:193510]: WS2 is a genetically heterogeneous, autosomal dominant disorder characterized by sensorineural deafness, pigmentary disturbances, and absence of dystopia canthorum. The frequency of deafness is higher in WS2 than in WS1. {ECO:0000269|PubMed:28236341, ECO:0000269|PubMed:8589691}. The disease is caused by mutations affecting the gene represented in this entry.; Waardenburg syndrome 2, with ocular albinism, autosomal recessive (WS2-OA) [MIM:103470]: A disorder characterized by the association of features typical of Waardenburg syndrome type 2 with ocular albinism. Patients manifest reduced visual acuity, albinotic fundus, deafness, hypomelanosis. {ECO:0000269|PubMed:9647758}. The disease is caused by mutations affecting the gene represented in this entry.; Tietz albinism-deafness syndrome (TADS) [MIM:103500]: An autosomal dominant disorder characterized by generalized hypopigmentation and congenital, bilateral, profound sensorineural deafness. {ECO:0000269|PubMed:10851256}. The disease is caused by mutations affecting the gene represented in this entry.; Melanoma, cutaneous malignant 8 (CMM8) [MIM:614456]: A malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites. {ECO:0000269|PubMed:22012259, ECO:0000269|PubMed:22080950}. Disease susceptibility is associated with variations affecting the gene represented in this entry.; Coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness (COMMAD) [MIM:617306]: An autosomal recessive syndrome characterized by severe microphthalmia, profound congenital sensorineural hearing loss, lack of pigment in the hair, skin, and eyes, macrocephaly, facial dysmorphism, and osteopetrosis. {ECO:0000269|PubMed:27889061}. The disease is caused by mutations affecting the gene represented in this entry. An allelic combination involving at least one dominant-negative mutation, inherited in a recessive manner, represents the underlying molecular mechanism leading to COMMAD syndrome. {ECO:0000269|PubMed:27889061}.; Variations affecting this gene are associated with susceptibility to pheochromocytomas and paragangliomas, rare neural crest-derived tumors with an approximate incidence of 1:300,000/year. {ECO:0000269|PubMed:27680874}.
General Description of Microphthalmia Transcription Factor .
This antibody reacts with a 52-56 kDa protein known as microphthalmia (Mi). This antibody reacts with both melanocytic and non-melanocytic isoforms of Mi. Mi is a basic helix-loop-helix-leucine zipper (b-HLH-ZIP) transcription factor implicated in pigmentation, mast cells and bone development. There are two known isoforms of Mi differing by 66 amino acids at the amino terminus.

Antibody (Suitable for clinical applications)

Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
Application Notes
Specification Recommendation
Recommended Dilution (Conc) 1:50-1:100
Pretreatment EDTA Buffer pH 8.0
Incubation Parameters 30 min at Room Temperature

Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.

Clonality: Monoclonal
Anti-Microphthalmia Transcription Factor Antibody Clone: D5
Host and Isotype: Mouse IgG1
Recommended Positive Control Sample: Melanoma
Cellular Localization of Antibody D5 Staining: Nuclear
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: BALB/C mice were injected with N-terminal fragment of human Mi protein.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.

Microphthalmia Transcription Factor Information for Pathologists

Limitations and Warranty

This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.

There are no reviews yet.

Be the first to review “Microphthalmia Transcription Factor [D5] Antibody (cGMP).”

Your email address will not be published. Required fields are marked *

Share a Protocol (View Reviewed Protocols Below)

Protocol Title

Materials

Methods

Notes


  protocol submission gif
enQuire Bio, LLC   8420 S Continental Divide Rd, #202   Littleton, CO 80127
Chat: See lower right corner. | enquire@enquirebio.com | Fax: 1-720-897-3730
Customer Service Available M-F 8AM-6PM MST or 24/7 Via Email

Microphthalmia Transcription Factor [D5] Antibody (cGMP).